CAAR T Cells: Precision Cellular Therapeutics for Antigen-Specific B Cell Depletion

Time: 3:50 pm
day: Day One


  • Chimeric autoantibody receptors (CAARs) direct potent and specific T cell killing of autoantigen-specific B cells
  • Specific elimination of pathogenic B cells with sparing of normal B cells may lead to long-term remission of B cell-mediated autoimmune disease without the risks of generalized immunosuppression
  • CAAR T cell therapeutics are under investigation for pemphigus vulgaris, myasthenia gravis, and other B cell-mediated autoimmune diseases